Crossmark

Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV)

Crossref DOI link: https://doi.org/10.1186/s13063-023-07862-4

Published Online: 2024-01-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Baos, Sarah

Todd, Rachel

Thirard, Russell

Harris, Rosie

Kirwan, Jana

Joyce, Katherine

Hutton, David

Finn, Adam

Clout, Madeleine

Cappel-Porter, Heike

Rogers, Chris A

Lazarus, Rajeka

Culliford, Lucy
Funding

Funding for this research was provided by:

National Institute for Health Research Policy Research Programme (PR-R17-0916-22001, NIHR203243)
License Information

Text and Data Mining valid from 2024-01-11

Version of Record valid from 2024-01-11
More Information

Article History

Received: 28 June 2023

Accepted: 8 December 2023

First Online: 11 January 2024

Declarations

:

: Ethical review and approval was provided by South Central - Berkshire Research Ethics Committee (21/SC/0100). Informed consent was received from all trial participants.

: Not applicable.

: RL reports being the Principle and Chief Investigator for studies sponsored by commercial organisations including Moderna, Janssen, Astra-Zeneca, and Valneva. Consultation fees received for professional services funded by Sanofi and Astra-Zeneca. SB, LC and CAR reports grants from NIHR, during the conduct of the trial. AF reports grants from Pfizer during the conduct of the trial, and grants from Elizabeth Blackwell Institute, Sanofi Pasteur, VBI Vaccines, Pfizer, Janssen, GSK, MedImmune, Novavax, and Valneva outside the submitted work. All other authors, RTo, RTh, RH, JK, KJ, DH, MC and HCP, declare no competing interests.

Document is current

Any future updates will be listed below